Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Zura Bio Ltd reported that Chief Executive Officer Sandeep Chidambar Kulkarni received an award of employee share options covering 894,000 Class A Ordinary Shares. The options have an exercise price of 6.03 per share and expire on April 1, 2036.

According to the vesting terms, one fourth of the options will vest on April 1, 2027, and the remaining three fourths will vest in equal quarterly installments thereafter, contingent on his continuous service. Following this grant, he holds 894,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kulkarni Sandeep Chidambar

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Share Option (Right to Buy)	894,000	$0.00	--

Holdings After Transaction: Employee Share Option (Right to Buy) — 894,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 894,000 options Exercise price: 6.03 per share Underlying shares: 894,000 shares +3 more

6 metrics

Option grant size 894,000 options Employee Share Option award to CEO

Exercise price 6.03 per share Strike price for Class A Ordinary Shares

Underlying shares 894,000 shares Class A Ordinary Shares subject to options

Options after grant 894,000 options Total derivative securities following transaction

Cliff vesting date April 1, 2027 One fourth of options vest on this date

Expiration date April 1, 2036 Option award expiration

Key Terms

Employee Share Option, Class A Ordinary Shares, vesting, exercise price, +1 more

5 terms

Class A Ordinary Shares financial

"underlying_security_title: "Class A Ordinary Shares""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

vesting financial

"shares subject to the option award shall vest on April 1, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: "6.0300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-04-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 06:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Sandeep Chidambar

(Last)

(First)

(Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON

NEVADA

89014

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Share Option (Right to Buy)	$6.03	04/01/2026		A		894,000		⁽¹⁾	04/01/2036	Class A Ordinary Shares	894,000	$0	894,000	D

Explanation of Responses:

1. One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Zura Bio (ZURA) disclose about CEO Sandeep Kulkarni’s latest equity award?

Zura Bio disclosed that CEO Sandeep Chidambar Kulkarni received an employee share option grant for 894,000 underlying Class A Ordinary Shares. These options form part of his compensation and give him the right to buy shares at a fixed exercise price if they vest.

How many options did the Zura Bio (ZURA) CEO receive in this grant?

The CEO received an option award over 894,000 underlying Class A Ordinary Shares. This grant increases his potential future equity exposure, subject to vesting and exercise conditions, aligning his incentives with long-term company performance and shareholder value over the option term.

What is the exercise price of the Zura Bio (ZURA) CEO’s new options?

The options granted to the Zura Bio CEO carry an exercise price of 6.03 per share. This means he can purchase Class A Ordinary Shares at 6.03 per share once the options vest and before they expire, potentially benefiting if the market price exceeds this level.

When do the new Zura Bio (ZURA) CEO options start vesting and how?

One fourth of the CEO’s option award vests on April 1, 2027. The remaining three fourths vest in equal quarterly installments afterward, provided he maintains continuous service. This time-based schedule encourages long-term retention and sustained leadership stability at the company.

What is the expiration date of the Zura Bio (ZURA) CEO option award?

The employee share options granted to the Zura Bio CEO expire on April 1, 2036. He must exercise vested options before this expiration date; otherwise, any unexercised options lapse and no longer provide the right to purchase the underlying Class A Ordinary Shares.

How many derivative securities does the Zura Bio (ZURA) CEO hold after this transaction?

After this grant, the CEO is reported as directly holding 894,000 derivative securities in the form of employee share options. This figure reflects the total options from this award, which may vest over time according to the specified schedule and service conditions.